Breakthru Psychiatric Solutions LLC

Prism for more than PTSD We are excited to share additional insight about Prism, the innovative, FDA-cleared device for the treatment of PTSD. Designed to help patients gain control over their symptoms and improve their quality of life, Prism is making a significant impact. A study published on IntechOpen (linked below) highlights the role of the amygdala in anxiety disorders, including generalized anxiety disorder (GAD). The study explains how hyperactivity of the amygdala and poor emotional regulation contribute to these conditions. Prism for PTSD leverages cutting-edge technology to help patients regulate their amygdala activity. While primarily designed for PTSD, Prism shows promise when used off-label for anxiety. By providing patients with the ability to control their amygdala network, Prism may offer significant symptomatic improvement for those struggling with GAD. Visit our website to learn more about Prism and how it can make a difference. https://zurl.co/U5WFD #MentalHealth #PTSD #Anxiety #InnovativeTreatment #GAD #Prism #PrismforPTSD #BreakthruPsych #Interventional

National Eating Disorders Awareness Week: Highlighting the Efficacy of TMS in Treating Anorexia Nervosa ? National Eating Disorders Awareness Week (NEDAW)?serves to educate about the realities of eating disorders and provide hope and visibility to individuals and loved ones impacted by these conditions.? ? This NEDAW (February 24 – March 2, 2025), we want to shed light on a promising treatment for anorexia nervosa: Transcranial Magnetic Stimulation (TMS). ? A recent systematic review and meta-analysis published in ???????????? ?????? ???????????? ?????????????????? - ?????????????? ???? ????????????????, ?????????????? ?????? ???????????????has shown that TMS can be an effective treatment for anorexia. The study, which analyzed data from multiple clinical trials, found that TMS significantly reduced symptoms of anorexia in 65% of participants. Additionally, the study reported a 50% improvement in quality-of-life scores among those treated with TMS. ? Breakthru is committed to providing innovative and effective treatments for mental health conditions. As providers of TMS therapy, we are encouraged by these findings and remain dedicated to offering cutting-edge treatments to our patients. If you or someone you know is battling an eating disorder, please reach out to us to learn more about how we can help. ? https://lnkd.in/erF8d-6d ? #NEDAwareness #EatingDisorders #MentalHealth #TMS #AnorexiaTreatment #BreakthruPsychiatricSolutions #BreakthruPsych #NEDAW

Recent findings from a systematic review in Translational Psychiatry highlight the rapid and effective treatment of suicidal ideation and depression using IV ketamine and S-ketamine (Spravato), with multi-dose administrations showing particularly strong results. In clinical trials, multiple doses of IV ketamine/S-ketamine reduced suicidal ideation scores by up to 50% within the first 24 hours, with sustained effects observed in follow-up assessments. Key takeaways from the review: Lasting effects: Multiple doses of IV ketamine/S-ketamine have shown significant reductions in suicidal ideation for several days to weeks. Consistency: Single doses of IV ketamine also demonstrated positive, though more variable, effects. Tolerability: Both IV ketamine and S-ketamine are well tolerated, making them viable options for treatment. In summary, the review supports the time-limited, anti-suicidal ideation effects of ketamine. These findings underscore the importance of personalized treatment approaches and offer hope for those struggling with severe depression and suicidal thoughts. Breakthru is proud to offer such treatments, in the forms of IV ketamine and Spravato. Read more about this promising research here: https://zurl.co/W5FkR #MentalHealth #Depression #SuicidePrevention #Ketamine #Research #HealthcareInnovation #BreakthruPsych #TRD #MDD #Spravato

Combination therapies for treatment-resistant depression and other mental health conditions are on the rise in interventional psychiatry. What if you could combine the power of treatments like IV ketamine and transcranial magnetic stimulation (TMS)? Current data shows that these therapies work together synergistically to enhance their benefits. According to the systematic review of these two modalities for treatment-resistant depression below, “The combination therapy showed a higher efficacy compared to monotherapies of either TMS or ketamine alone." This underscores Breakthru's commitment to providing cutting-edge, effective treatments that offer enhanced outcomes for our patients. Discover how our integrated approach and combination therapies can make a difference. #DepressionTreatment #InterventionalPsychiatry #KetamineTherapy #TMSTherapy #TMS #MentalHealth #BreakthruPsych #TRD https://zurl.co/k1Iiw

We are thrilled to announce that Dr. Giles has been featured in The Atlantan's recent issue as one of Atlanta's influential women! "Grateful for this opportunity to share about Breakthru with Atlantans! Honored to be recognized for the work we do in improving access to interventional psychiatric treatments for Georgians," Dr. Giles shared. #InfluentialWomenOfAtlanta #TheAtlantan #Psychiatry #InterventionalPsychiatry #Psychiatrist #BreakthruPsych

Breakthru goes to Texas! Dr. Karen Giles and Dr. Cecilia Kwong attended the ASKP3 Annual Conference in Austin last week, gaining insights into the latest research and resources in ketamine and emerging treatments. Dr. Giles noted, "The conference validated the way that IV ketamine and Spravato treatments are performed at Breakthru in terms of quality of care, safety, innovation, and collaboration." At Breakthru, we prioritize: Quality of Care & Safety: Emphasizing close follow-up for patients undergoing ketamine-based treatments, with personalized consultations and follow-up visits covered by insurance. ?? Innovation: Combining IV ketamine and TMS to capture the synergy of these treatments, and offering combination treatments of IV ketamine/Spravato and Prism for targeting PTSD and anxiety. Collaboration: Working with primary psychiatrists and therapists to ensure comprehensive patient support during the healing process from depression, anxiety, PTSD, OCD, and eating disorders. Our doctors remain committed to staying up to date on new developments in interventional psychiatry and bringing this knowledge to our patients at Breakthru. #BreakthruPsychiatricSolutions #ASKP3Conference #MentalHealthInnovation #QualityCare #PatientSafety #CollaborativeCare #MentalHealthMatters #InterventionalPsychiatry #Breakthru #BreakthruPsych #Spravato #TMS

AJP's Groundbreaking Issue on Psychedelic Medicine: A New Era of Research The latest issue of The American Journal of Psychiatry (AJP) is dedicated to the growing field of psychedelic medicine, emphasizing the importance of scientific rigor in this area. This month's special issue features a series of studies on using psychedelics like LSD and psilocybin to treat various mental health conditions, such as treatment-resistant depression, anxiety, PTSD, alcohol use disorder, and more. It also examines critical questions, such as whether patients can gain the therapeutic advantages of psychedelics without entering an altered state of consciousness, and how these substances interact with the psychological support and therapy aspects of treatment. Here are some other key topic highlights: Pharmacology and Neural Effects: The issue includes comprehensive reviews on the basic pharmacology of psychedelics and their effects on neural circuits, providing a foundational understanding of how these substances interact with the brain. Clinical Efficacy: Scott T. Aaronson, M.D., and colleagues present findings from a trial demonstrating the safety and efficacy of synthetic psilocybin for treatment-resistant depression. This study highlights the potential of psychedelics as a viable treatment option for severe mental health conditions. Methodological Guidance: The issue offers recommendations for conducting rigorous psychedelic clinical trials to ensure that future research is methodologically sound and clinically relevant. Short-Acting Psychedelics: Johannes G. Ramaekers, Ph.D., reviews the potential benefits of ultra-fast, short-acting psychedelics like DMT and 5-MeO-DMT. These substances may offer advantages such as individualized dosing regimens and less complex implementation. Risk Assessment: Sharmin Ghaznavi, M.D., Ph.D., discusses the known and potential risks associated with psychedelic treatments, including perceptual disturbances, cardiovascular effects, and the potential for misuse. The article emphasizes the need for ongoing research and monitoring to mitigate these risks. This special issue underscores the critical need for scientific rigor in the study of psychedelic medicine. By addressing fundamental questions and methodological challenges, the research presented in AJP paves the way for the development of safe and effective psychedelic therapies. The potential for these treatments is promising, but there is still much work to be done to ensure their clinical success. Breakthru is committed to staying at the forefront of research and developments in the use of psychedelics for treating treatment-resistant mental health disorders. Follow us to stay informed about the latest advancements and insights in this rapidly evolving field! https://zurl.co/ADkMN https://zurl.co/W2rlU

Exciting news!??? We're thrilled to announce that Spravato? (esketamine) has been approved by the FDA as the first and only monotherapy for treatment-resistant depression! This means patients no longer need to be on a current antidepressant to qualify for treatment. Persistent depression that is unresponsive to traditional treatments affects more than 40% of people with depression. This groundbreaking approval offers new hope for those struggling with major depressive disorder, increasing access to rapid and significant symptom relief. Contact us today to learn more about this innovative treatment and how it can make a difference in your life. Visit our website to submit an appointment request or call us at 470-231-2235. #MentalHealth #DepressionTreatment #TRD #TreatmentResistant #Spravato #Esketamine #BreakthruPsychiatricSolutions Read more about the FDA's approval here: https://lnkd.in/ep6xDGJu

Depression causes structural changes in your brain that perpetuate your symptoms and resist traditional treatments. TMS reactivates your altered neural pathways and restores your brain’s mood control —?click the link to find out how in our newest blog post! https://lnkd.in/gMpmJKmW

Innovative Mental Health Treatments at Breakthru Psychiatric Solutions??? At Breakthru, we are dedicated to providing cutting-edge treatments tailored to individual mental health needs. Our latest infographic showcases the unique and overlapping treatments for treatment-resistant Depression, PTSD, and Anxiety. ???Depression: Vagus Nerve Stimulation (VNS), Spravato, Transcranial Magnetic Stimulation (TMS), IV Ketamine ???PTSD: Prism, IV Ketamine ???Anxiety: TMS, Prism, IV Ketamine We believe in a personalized approach to mental health care, ensuring that each patient receives the most effective treatment for their condition. Visit our website and contact us today to explore how our innovative solutions can make a difference in your mental health journey. #MentalHealth #Depression #PTSD #Anxiety #MentalHealthCare #InnovativeTreatments #BreakthruPsychiatricSolutions #BreakthryPsych #TreatmentResistant